Targeted HA degradation enhancement of ICIs efficacy by facilitating TIL recruitment was assessed by characterizing TAVO423 trispecific AbEn in combination with anti-PD-1 therapy in immunocompetent mice bearing EMT-6 syngeneic breast tumors. This evidence concerns the gene PDCD1 and breast neoplasm.